Aurlumyn FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 21, 2024.
FDA Approved: Yes (First approved February 13, 2024)
Brand name: Aurlumyn
Generic name: iloprost
Dosage form: Injection
Company: Eicos Sciences Inc.
Treatment for: Frostbite
Aurlumyn (iloprost) is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations.
- Frostbite is an injury caused by skin exposure to freezing conditions. Severe frostbite occurs when both the skin and underlying tissue are frozen and the blood flow is stopped, which may result in ischemic tissue injury and necrosis. Severe cases may require amputation.
- Aurlumyn contains iloprost, which is a synthetic analog of prostacyclin PGI2. Iloprost works as a vasodilator and an inhibitor of platelet aggregation.
- Iloprost was first approved in 2004 as an inhalation solution formulation under the brand name Ventavis for the treatment of pulmonary arterial hypertension.
- Aurlumyn is administered by continuous intravenous infusion for 6 hours each day up to a maximum of 8 consecutive days.
- Warnings and precautions include symptomatic hypotension.
- Common adverse reactions include headache, flushing, palpitations/tachycardia, nausea, vomiting, dizziness, and hypotension.
Development timeline for Aurlumyn
| Date | Article |
|---|---|
| Feb 14, 2024 | Approval FDA Approves Aurlumyn (iloprost) as the First Medication to Treat Severe Frostbite |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
